Cri-du-chat is a genetic disorder that is caused by a deletion of the short arm of chromosome 5. The name of the syndrome, meaning cat cry was coined after the main clinical finding of a high-pitched, monochromatic cat-like cry. The clinical picture, severity, and progression of the disease vary depending on the region of the chromosome that is deleted and whether it is terminal or interstitial. In other words, differences in phenotype can be attributed to the differences in genotype. This disorder is often characterized by distinctive facial features, delayed development, and intellectual disability. ,
Cri-du chat is caused by either a partial or complete deletion of chromosome 5p. Most of the deletions occur de novo. The deletions occur as random events during the formation of reproductive cells in early fetal development. Around 80% to 90% are paternal in origin, which can arise from a chromosomal breakage during gamete formation. The remaining 10% to 15% are a result of unbalanced parental translocation. Moreover, 80% to 90% of cases result from terminal deletions of chromosome 5 while 3% to 5% are due to an interstitial deletion. Mosaicism, inversions, and ring chromosomes are less common mechanisms.
Although cri du chat is considered a rare disorder, it is one of the most common chromosomal anomalies. The incidence ranges from 1:15,000 to 1:50,000 liveborn infants. The incidence in females is slightly higher than males. The exact incidence and prevalence worldwide and among races has not been established. Similarly, specific risk factors associated with prenatal events or parental age have not been established. However, there are occasional reports of parental exposure to radiation, hyperemesis, anorexia, and toxemia.
Patients demonstrate phenotypic and genotypic variability. A partial deletion of the short arm of chromosome 5 has been found to be the cause for the characteristic phenotype. The phenotype being identifiable in spite of variations in deletion size has led to a theory that a critical region is responsible for the characteristic feature in hemizygosity. The region identified is 5p15.2, and individuals with a deletion of chromosome 5 that do not include this region do not show a typical phenotype and, in some cases, are even normal.
Cytogenetic studies have helped identify two regions, 5p15.3, which is responsible for the characteristic cry, and 5p15.2 which is responsible for the other major clinical findings. Similarly, other regions have been identified for other features such as speech retardation and dysmorphism. Therefore, the clinical manifestations depend on the deletion of the critical region. Another important factor for the manifestation is the size as well as the type of deletion and whether it is interstitial or terminal.
The most characteristic feature of this disease is high-pitched crying, and the pathogenesis can be attributed to the anatomical alteration of the laryngeal morphology which may be a result of:
However, not all patients with abnormal crying have the above features. Therefore, there may be neurological changes as well.
In the neonatal period, the most characteristic finding is a high-pitched, monotonous cry, which normally disappears within the first few months of life. The cry is not limited to this syndrome alone and has been reported in a few other neurological disorders. Newborns also exhibit low birthweight and microcephaly as well as asphyxia, muscle hypotonia, and impaired suction. These lead to impaired growth and development during the first few years of life. Recurrent respiratory, as well as intestinal infections, have been reported. 
(a) Craniofacial malformations:
With increasing age, the following features change:
(b) Other anomalies that might be present:
(c) Orofacial abnormalities:
(d) Developmental and behavioral manifestations:
Cri du chat can be diagnosed with amniocentesis during the antenatal period where deletion of chromosome 5 will be seen. The structural abnormalities can be observed sonographically. Also, fetuses who show mosaicism may display fetoplacental and fetoamniotic chromosomal abnormalities along with microcephaly and cerebellar hypoplasia. 
A diagnosis can be made based on clinical findings. The occurrence of certain characteristic findings such as microcephaly, low birthweight, moon face, muscle hypotonia, and a cat-like cry together should raise clinical suspicion of the condition. Sometimes this can be difficult because the features may not be obvious as patients show a cytogenetic variation leading to phenotypic variation. The clinical features, as well as the severity and prognosis, can be determined by the size and position of the deletion.
If clinical suspicion is present, one of the first tests that can confirm the diagnosis is a karyotype analysis. However, in cases where the clinical suspicion is high in the presence of a normal karyotype further specific tests can be carried out such as FISH (fluorescence in-situ hybridization), CGH (comparative genomic hybridization), or quantitative PCR (polymerase chain reaction).
FISH has led to an improvement in the diagnosis of genetic disorders caused by chromosome deletion and has provided a phenotypic map and the associated genome of an individual. Newer techniques, such as CGH, has opened up new doors by including the whole genome and the associated markers which can identify genetic alterations.
There have been very few studies on the MRI findings. However, pontine hypoplasia seems to be the most common feature. This is associated with other findings such as cerebellar hypoplasia and microcephaly as well as corpus callosum anomalies. Supratentorial abnormalities also have been observed. 
There is no specific treatment for patients due to the early onset of cerebral damage during embryonal development. However, patients benefit from rehabilitation, especially when it is provided early. This has shown to improve prognosis as well as social adaptation.
During the neonatal period, physical therapy should be started in the first week of life to help with any difficulty in swallowing and suction. Breastfeeding is still possible, and intensive care is rarely necessary.
Physical therapy, psychomotricity, and speech therapy are suggested for psychomotor and speech retardation. Patients often have sensorineural deafness; therefore, audiometric examinations should be carried out in all children. Other helpful treatments include surgery, special diet, and healthy routines.
Families should be involved in the care of the patient. They should be provided with information about the disease and available support groups.
Morbidity and mortality rates decrease after the first few years of life. It is reported that 75% of deaths occur during the first month of life, and about 90% of deaths occur during the first year. It is important to note that the type, size, and location of the deletion(s) greatly influence the prognosis.
One of the most important factors in the prognosis of the disease is an early diagnosis. Early diagnosis allows for the implementation of therapeutic measures early on to improve the outcome of physical as well as psychomotor development and helps with social adaptation. 
Cri du chat is managed by an interprofessional team that includes, nurses, therapists, social workers and dietitians. There is no specific treatment for patients due to the early onset of cerebral damage during embryonal development. However, patients benefit from rehabilitation, especially when it is provided early. This has shown to improve prognosis as well as social adaptation. During the neonatal period, physical therapy should be started in the first week of life to help with any difficulty in swallowing and suction. Breastfeeding is still possible, and intensive care is rarely necessary.
Unfortunately outcomes for infants with this disorder are poor. They face numerous difficulties with feeding, breathing and development. Most die within the first few months but those with mild deficits may live longer.
|||Cri-Du-Chat Syndrome: Clinical Profile and Chromosomal Microarray Analysis in Six Patients., Espirito Santo LD,Moreira LM,Riegel M,, BioMed research international, 2016 [PubMed PMID: 27144168]|
|||Cri du chat syndrome: a critical review., Rodríguez-Caballero A,Torres-Lagares D,Rodríguez-Pérez A,Serrera-Figallo MA,Hernández-Guisado JM,Machuca-Portillo G,, Medicina oral, patologia oral y cirugia bucal, 2010 May 1 [PubMed PMID: 20038906]|
|||Cri du Chat syndrome., Cerruti Mainardi P,, Orphanet journal of rare diseases, 2006 Sep 5 [PubMed PMID: 16953888]|
|||Corrêa T,Feltes BC,Riegel M, Integrated analysis of the critical region 5p15.3-p15.2 associated with cri-du-chat syndrome. Genetics and molecular biology. 2019 Apr 11; [PubMed PMID: 30985858]|
|||Liverani ME,Spano A,Danesino C,Malacarne M,Cavani S,Spunton M,Guala A, Children and adults affected by Cri du Chat syndrome: Care's recommendations. Pediatric reports. 2019 Feb 26; [PubMed PMID: 30838120]|
|||Vado Y,Errea-Dorronsoro J,Llano-Rivas I,Gorria N,Pereda A,Gener B,Garcia-Naveda L,Perez de Nanclares G, Cri-du-chat syndrome mimics Silver-Russell syndrome depending on the size of the deletion: a case report. BMC medical genomics. 2018 Dec 27; [PubMed PMID: 30587166]|
|||Huisman S,Mulder P,Kuijk J,Kerstholt M,van Eeghen A,Leenders A,van Balkom I,Oliver C,Piening S,Hennekam R, Self-injurious behavior. Neuroscience and biobehavioral reviews. 2018 Jan; [PubMed PMID: 28694012]|
|||Corcuera-Flores JR,Casttellanos-Cosano L,Torres-Lagares D,Serrera-Figallo MÁ,Rodríguez-Caballero Á,Machuca-Portillo G, A systematic review of the oral and craniofacial manifestations of cri du chat syndrome. Clinical anatomy (New York, N.Y.). 2016 Jul; [PubMed PMID: 26457586]|
|||Nguyen JM,Qualmann KJ,Okashah R,Reilly A,Alexeyev MF,Campbell DJ, 5p deletions: Current knowledge and future directions. American journal of medical genetics. Part C, Seminars in medical genetics. 2015 Sep; [PubMed PMID: 26235846]|
|||Méndez-Rosado LA,García D,Molina-Gamboa O,García A,de León N,Lantigua-Cruz A,Liehr T, Algorithm for the diagnosis of patients with neurodevelopmental disorders and suspicion of a genetic syndrome. Archivos argentinos de pediatria. 2020 Feb; [PubMed PMID: 31984699]|